Explore

Trendline Trendline
AN2 Therapeutics Advances Multiple Clinical Programs with Boron Chemistry Platform

AN2 Therapeutics Advances Multiple Clinical Programs with Boron Chemistry Platform

AN2 Therapeutics Advances Multiple Clinical Programs with Boron Chemistry Platform
Trendline Trendline
Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaboration
Trendline Trendline
Inhibrx to Present Interim Results of INBRX-106 Study in Head and Neck Cancer

Inhibrx to Present Interim Results of INBRX-106 Study in Head and Neck Cancer

Inhibrx to Present Interim Results of INBRX-106 Study in Head and Neck Cancer
Trendline Trendline
Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial

Anixa Biosciences Announces Positive Survival Data from Phase 1 Ovarian Cancer CAR-T Therapy Trial
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development
Trendline Trendline
Ankyra Therapeutics Presents Preclinical Data on Anchored Immunotherapy at PEGS Boston 2026

Ankyra Therapeutics Presents Preclinical Data on Anchored Immunotherapy at PEGS Boston 2026

Ankyra Therapeutics Presents Preclinical Data on Anchored Immunotherapy at PEGS Boston 2026
Trendline Trendline
Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer

Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer

Halia Therapeutics to Present Phase 2 Ofirnoflast Data and Appoints New Chief Medical Officer
Trendline Trendline
Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers
Trendline Trendline
AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics
Trendline Trendline
Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress

Incyte to Present Key Hematology and Oncology Data at EHA 2026 Congress
Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies

BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies

BeOne Medicines Honored as 'Outstanding Global Oncology Company' for Advancements in Cancer Therapies